Abstract: Method of treating or diagnosing cancers involving P-cadherin expression are provided using ligands that target P-cadherin, especially human anti-P-cadherin antibodies. Also provided are screens for identifying anti-P-cadherin antibodies having therapeutic activity.

Abstract: Compositions incorporating small interfering ribonucleic acid (siRNA) and certain lipid-conjugated polyamide compound-based delivery vehicles that are particularly useful in the delivery siRNA and other polynucleotides to cells. Also, methods of making and using the compositions.

Abstract: This invention relates to novel human polynucleotides and variants thereof, their encoded polypeptides and variants thereof, to genes corresponding to these polynucleotides and to proteins expressed by the genes. The invention also relates to diagnostic and therapeutic agents employing such novel human polynucleotides, their corresponding genes or gene products, e.g., these genes and proteins, including probes, antisense constructs, and antibodies.

Abstract: The present invention provides polynucleotides, as well as polypeptides encoded thereby, that are differentially expressed in cancer cells. These polynucleotides are useful in a variety of diagnostic and therapeutic methods. The present invention further provides methods of reducing growth of cancer cells. These methods are useful for treating cancer.

Abstract: The present invention is directed to methods of treating and preventing cancer, such as cancer characterized by differential expression of trefoil factor 3 (TFF3). The methods include administering to a patient an agent that modulates TFF3 activity or expression. The present invention is further directed to reducing the physiological effects of TFF3 expression in cells, including inhibiting cell motility and resistance to apoptosis. Oligonucleotides and antibodies that can modulate expression or activity of TFF3 are also provided.

Abstract: The present invention provides polynucleotides, as well as polypeptides encoded thereby, that are differentially expressed in cancer cells. These polynucleotides are useful in a variety of diagnostic and therapeutic methods. The present invention further provides methods of reducing growth of cancer cells. These methods are useful for treating cancer.

Abstract: The present invention provides methods for identification of cancerous cells by detection of expression levels of TTK, as well as diagnostic, prognostic and therapeutic methods that take advantage of the differential expression of these genes in mammalian cancer. Such methods can be useful in determining the ability of a subject to respond to a particular therapy, e.g., as the basis of rational therapy. In addition, the invention provides assays for identifying pharmaceuticals that modulate activity of these genes in cancers in which these genes are involved, as well as methods of inhibiting tumor growth by inhibiting activity of TTK.

Abstract: The present invention provides methods for identification of cancerous cells by detection of expression levels of TTK, as well as diagnostic, prognostic and therapeutic methods that take advantage of the differential expression of these genes in mammalian cancer. Such methods can be useful in determining the ability of a subject to respond to a particular therapy, e.g., as the basis of rational therapy. In addition, the invention provides assays for identifying pharmaceuticals that modulate activity of these genes in cancers in which these genes are involved, as well as methods of inhibiting tumor growth by inhibiting activity of TTK.

Abstract: The present invention provides methods for identification of cancerous cells by detection of expression levels of TTK, as well as diagnostic, prognostic and therapeutic methods that take advantage of the differential expression of these genes in mammalian cancer. Such methods can be useful in determining the ability of a subject to respond to a particular therapy, e.g., as the basis of rational therapy. In addition, the invention provides assays for identifying pharmaceuticals that modulate activity of these genes in cancers in which these genes are involved, as well as methods of inhibiting tumor growth by inhibiting activity of TTK.

Abstract: Human HAKAI (hsHAKAI), an E3-ubiquitin ligase, can be inhibited to treat proliferative disorders, such as cancers, dysplasias and hyperplasias. Effective levels of hsHAKAI can be inhibited, for example, using antisense oligonucleotides, ribozymes, interference RNA, and antibodies. Test compounds can be screened for binding to hsHAKAI, for disruption of hsHAKAI-E-cadherin binding, or for inhibition of hsHAKAI enzymatic activity to identify therapeutic compounds for treating proliferative disorders.

Abstract: Inhibitors of TSPAN-7 are provided that reduce the expression or biological activities of TSPAN-7 in a mammalian cell. TSPAN-7 inhibitors include antisense molecules, ribozymes, antibodies and antibody fragments, proteins and polypeptides as well as small molecules. TSPAN-7 inhibitors find use in compositions and methods for decreasing TSPAN-7 gene expression as well as methods for inhibiting proliferation of mammalian cells, including tumor cells, methods for decreasing the side effects of cancer therapy and methods for treating neoplastic diseases. Also provided are nucleic acids encoding a new member of the tetraspan family, TSPAN-7, and polypeptides encoded thereby.

Abstract: Inhibitors of human Akt3, including antisense oligonucleotides, methods, and compositions specific for human Akt3, are provided. Methods of using the compositions for modulating Akt3 expression and for regulating cell growth, particularly tumor cell growth, are also provided.

Abstract: This invention relates to novel human polynucleotides and variants thereof, their encoded polypeptides and variants thereof, to genes corresponding to these polynucleotides and to proteins expressed by the genes. The invention also relates to diagnostic and therapeutic agents employing such novel human polynucleotides, their corresponding genes or gene products, e.g., these genes and proteins, including probes, antisense constructs, and antibodies.

Abstract: A human gene encoding a novel cyclin-dependent kinase termed hPNQALRE and its expression products can be used to provide reagents and methods for detecting neoplasia. Compositions and methods for treating proliferative disorders and neoplasia are also provided.

Abstract: Inhibitors of human Nek2, including antisense oligonucleotides, methods, and compositions specific for human Nek2, are provided. Methods of using the compositions for modulating Nek2 expression and for regulating cell growth, particularly tumor cell growth, are also provided.

Abstract: The present invention is directed toward the use of antisense oligonucleotides that target human kinesin genes for treating diseases involving aberrant cell proliferation, particularly cancers such as colon cancer. Also, the invention is directed to a synergistic combination for treating cancer comprising a chemotherapeutic such as cisplatin and an antisense oligonucleotide that specifically inhibits human kinesin expression.

Abstract: Method of treating or diagnosing cancers involving P-cadherin expression are provided using ligands that target P-cadherin, especially human anti-P-cadherin antibodies.

Abstract: The present invention provides a method for delivering polynucleotide agents, particularly oligonucleotides, to the CNS of a mammal by way of a neural pathway originating in the nasal cavity or through a neural pathway originating in an extranasal tissue that is innervated by the trigeminal nerve.

Abstract: A human gene encoding a novel cyclin-dependent kinase termed hPFTAIRE and its expression products can be used to provide reagents and methods for detecting migrating or metastasizing cells. Compositions and methods for treating proliferative disorders and neoplasia are also provided.

Abstract: This invention relates to novel human polynucleotides and variants thereof, their encoded polypeptides and variants thereof, to genes corresponding to these polynucleotides and to proteins expressed by the genes. The invention also relates to diagnostic and therapeutic agents employing such novel human polymucleotides, their corresponding genes or gene products, e.g., these genes and proteins, including probes, antisense constructs, and antibodies.